No Data
Puris (301257.SZ): The actual controller Lai Chunbao has accumulated a Shareholding of 0.0545 million shares.
On April 15, Gelonghui reported that Prise (301257.SZ) announced that as of the disclosure date of the announcement, the shareholding plan of the actual controller and Chairman, Mr. Lai Chunbao, has surpassed the halfway point. From January 15, 2025, to April 15, 2025, Mr. Lai Chunbao has cumulatively increased his shareholding in the company by 0.0545 million shares through the centralized bidding method via the Shenzhen Stock Exchange trading system, accounting for 0.07% of the company's total equity, with a total investment of 1.6768 million yuan (excluding transaction fees).
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Shareholder Zhang Jing of Prises (301257.SZ) has completed the shareholding reduction period, with a total reduction of 0.5912 million shares.
Puris (301257.SZ) announced that the Shareholder Zhang Jing's Shareholding plan has expired, with a total reduction in company shares...
SMO ClinPlus CO.,LTD.'s (SZSE:301257) Shares Bounce 28% But Its Business Still Trails The Market
Pursuis (301257.SZ): The internal office system has completed the localization access and deployment of DeepSeek.
On February 19, Gelonghui reported that Prise (301257.SZ) stated on the investor interaction platform that the company has always valued the development and application of digital intelligence and new technologies. Currently, the company's internal office system has completed the localization access and deployment of DeepSeek, enhancing work efficiency through intelligent interaction, and actively exploring the deep integration of AI technology and Business systems to improve the execution efficiency of clinical trials. However, the company has not signed a direct service cooperation agreement with DeepSeek, and this matter has no significant impact on the company's current main business operations.
Is SMO ClinPlus CO.,LTD.'s (SZSE:301257) Recent Stock Performance Tethered To Its Strong Fundamentals?